Research graph
References from Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. Local targets link to admitted publications; unresolved targets remain external evidence.
Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan
10.3201/eid2704.210138 · 2021 · External reference
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence
10.1038/s41591-021-01378-7 · 2021 · External reference
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
10.1126/science.abh2644 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Antibody evasion by the P.1 strain of SARS-CoV-2
10.1016/j.cell.2021.03.055 · 2021 · External reference
Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
10.1056/nejmc2103022 · 2021 · External reference
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
10.1016/j.cell.2021.03.036 · 2021 · External reference
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
10.1038/s41586-021-03471-w · 2021 · External reference
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
10.1016/s2666-5247(21)00068-9 · 2021 · External reference
Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
10.1016/s2666-5247(21)00129-4 · 2021 · External reference
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
10.1016/s1473-3099(21)00287-5 · 2021 · External reference
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
10.1016/s1473-3099(20)30843-4 · 2021 · External reference
10.1101/2021.03.31.21254494
10.1101/2021.03.31.21254494 · External reference
Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study
10.2139/ssrn.3822780 · 2021 · External reference
Unresolved reference
External reference
Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls
10.1016/j.vaccine.2017.04.037 · 2017 · External reference
Case-control vaccine effectiveness studies: Data collection, analysis and reporting results
10.1016/j.vaccine.2017.04.035 · 2017 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
10.1126/science.abe9728 · 2021 · External reference
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
10.1016/s0140-6736(21)00183-5 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
2000 · External reference
Unresolved reference
2000 · External reference
Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness
10.1093/aje/kww064 · 2016 · External reference
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
10.1016/s2213-2600(20)30560-9 · 2021 · External reference
A minimal common outcome measure set for COVID-19 clinical research
10.1016/s1473-3099(20)30483-7 · 2020 · External reference
Unresolved reference
External reference
10.1101/2021.05.19.21257472
10.1101/2021.05.19.21257472 · External reference
10.1101/2021.04.12.21255308
10.1101/2021.04.12.21255308 · External reference
Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality
10.1016/j.eclinm.2021.101036 · 2021 · External reference
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
10.1056/nejmc2101667 · 2021 · External reference
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
10.1038/s41591-021-01325-6 · 2021 · External reference
Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines
10.1101/2021.01.21.21250258 · 2021 · External reference
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
10.1136/bmj.n1088 · 2021 · External reference
Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers – a Danish cohort study
10.1101/2021.03.08.21252200 · 2021 · External reference
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
10.1016/s0140-6736(21)00575-4 · 2021 · External reference
Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area
10.1371/journal.pone.0245556 · 2021 · External reference
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
2021 · External reference
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
2021 · External reference
